Medicus pharma ltd announces submission of phase 2 clinical design (sknjct-004) to united arab emirates (uae) department of health (doh) to non-invasively treat basal cell carcinoma of the skin (bcc)

The clinical study is expected to randomize 36 participants in cleveland clinic abu dhabi (ccad) and three other clinical sites in uae the clinical study is expected to randomize 36 participants in cleveland clinic abu dhabi (ccad) and three other clinical sites in uae
BCC Ratings Summary
BCC Quant Ranking